Quality is Life — Laos Alliance Pharmaceutical Group

ລາວ/中文/EN

Manufacturing & innovation
Manufacturing Capabilities
Every dosage form we make
Manufacturing Network
Plants & 20 workshops
Research & Development
Labs, ATMP & formulation
Quality & GMP
Standards & traceability
Alliance Stem Cell Centre
Stem-cell, NK & exosome science
Integrated Value Chain
Farm → chemicals → finished
What we make
Every major dosage form, made to one GMP standard
Explore capabilities
NEWSROOM

Biotechnology

ALI-LENA Injection (lenacapavir) 463.5 mg / 1.5 mL vial product packaging
Product news
15 Jul 2026

ALI-LENA® Injection (lenacapavir) registered in Lao PDR

The Food and Drug Department has registered ALI-LENA® Injection (lenacapavir) 463.5 mg / 1.5 mL for subcutaneous use, indicated with other antiretrovirals for heavily treatment-experienced adults with multidrug-resistant HIV-1.
Alliance Pharma Group — six-month achievements 2026
Company
1 Jul 2026

A Driving Force in Southeast Asian Pharmaceutical Manufacturing

Alliance’s first-half 2026 highlights, from ASEAN expansion to advanced biopharmaceutical manufacturing.
ALIVOSO (vosoritide) 1.2 mg injection product packaging
Product news
24 Jun 2026

ALIVOSO® (vosoritide) registered in Lao PDR

The Food and Drug Department has registered ALIVOSO® (vosoritide) 1.2 mg powder for injection, indicated to increase linear growth in children with achondroplasia whose growth plates have not closed.
Become a partner
EN·ລາວ·中文